CoTherix Ventavis Clears FDA For Pulmonary Arterial Hypertension
This article was originally published in The Pink Sheet Daily
Executive Summary
Launch is planned for the second quarter following export clearance from regulators in Spain, where iloprost is manufactured. The timing will also allow CoTherix to hire and train the Ventavis sales force prior to making product available.
You may also be interested in...
CoTherix’ Ventavis Cleared For Combination Use
Ventavis’ expanded label addresses use of the inhaled pulmonary arterial hypertension therapy in combination with Actelion’s oral Tracleer.
CoTherix’ Ventavis Cleared For Combination Use
Ventavis’ expanded label addresses use of the inhaled pulmonary arterial hypertension therapy in combination with Actelion’s oral Tracleer.
Ventavis To Cost $65,000 - $100,000 Per Year, CoTherix Says
The PAH therapy is competitively priced against United Therapeutics' Remodulin and Actelion's Tracleer, CoTherix says. With its sales force still in training, Ventavis has launched ahead of schedule.